Empirical_JJ Bayesian_JJ data_NNS mining_NN for_IN discovering_VBG patterns_NNS in_IN post-marketing_JJ drug_NN safety_NN
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
estimation_NN of_IN the_DT parameters_NNS of_IN the_DT prior_JJ distribution_NN in_IN the_DT empirical_JJ Bayes_NNP model_NN ,_, a_DT summary_NN of_IN the_DT table_NN of_IN counts_NNS and_CC baseline_NN values_NNS ,_, computed_VBN using_VBG the_DT data_NNS squashing_VBG methods_NNS of_IN DuMouchel_NNP et_FW al_FW =_JJ -_: =[_NN 8_CD -RRB-_-RRB- -_: =_JJ -_: is_VBZ substituted_VBN for_IN the_DT much_RB larger_JJR baseline_NN values_NNS file_VBP ._.
5_CD ._.
USER_NNP INTERFACE_NNP &_CC CAPABILITIES_NNP The_NNP WebVDME_NNP user_NN interface_NN is_VBZ organized_VBN around_IN a_DT set_NN of_IN ``_`` tabs_NNS ''_'' and_CC links_NNS that_WDT lead_VBP to_TO major_JJ components_NNS of_IN the_DT
e_LS ``_`` a_DT priori_FW ''_'' method_NN to_TO prune_VB counting_NN of_IN higher-order_JJ associations_NNS when_WRB the_DT counts_NNS for_IN their_PRP$ component_NN lower-order_NN associations_NNS imply_VBP that_IN the_DT higher-order_JJ count_NN can_MD not_RB meet_VB a_DT minimum_JJ count_NN threshold_NN =_JJ -_: =[_NN 7_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Counting_VBG is_VBZ implemented_VBN using_VBG a_DT hash_JJ table_NN to_TO store_VB the_DT count_NN data_NNS ,_, with_IN an_DT ability_NN to_TO write_VB out_RP and_CC merge_VB partial_JJ results_NNS when_WRB working_VBG with_IN very_RB large_JJ problems_NNS that_WDT would_MD exceed_VB available_JJ physical_NN
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
adverse_JJ reactions_NNS -LRB-_-LRB- 1,2,3,4_CD -RRB-_-RRB- ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- =_JJ -_: =[_NN 5_CD -RRB-_-RRB- -_: =_JJ -_: and_CC at_IN the_DT Uppsala_NNP Monitoring_NN Centre_NNP where_WRB Edwards_NNP ,_, Lindquist_NNP ,_, Bate_NNP and_CC others_NNS have_VBP pursued_VBN the_DT use_NN of_IN techniques_NNS based_VBN on_IN Bayesian_JJ neural_JJ networks_NNS -LRB-_-LRB- 6_CD -RRB-_-RRB- ._.
GlaxoSmithKline_NN -LRB-_-LRB- ``_`` GSK_NNP ''_'' -RRB-_-RRB- and_CC Lincoln_NNP Technologie_NNP
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Monitoring_NN Centre_NNP where_WRB Edwards_NNP ,_, Lindquist_NNP ,_, Bate_NNP and_CC others_NNS have_VBP pursued_VBN the_DT use_NN of_IN techniques_NNS based_VBN on_IN Bayesian_JJ neural_JJ networks_NNS =_JJ -_: =[_NN 6_CD -RRB-_-RRB- -_: =_SYM -_: ._.
GlaxoSmithKline_NN -LRB-_-LRB- ``_`` GSK_NNP ''_'' -RRB-_-RRB- and_CC Lincoln_NNP Technologies_NNP -LRB-_-LRB- ``_`` Lincoln_NNP ''_'' -RRB-_-RRB- began_VBD a_DT collaboration_NN in_IN 2001_CD to_TO apply_VB safety_NN data_NNS mining_NN techniques_NNS both_DT to_TO provide_VB direct_JJ leverage_NN in_IN addressing_VBG GSK_NNP 's_POS core_NN business_NN pr_NN
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
